-
Michael Goettler, who runs Pfizer’s off-patent drug unit, would become chief executive of the combined firm.Mylan, whose shares have fallen almost 50% in the past year, has a market value of $9.5 billion
Michael Goettler, who runs Pfizer’s off-patent drug unit, would become chief executive of the combined firm.Mylan, whose shares have fallen almost 50% in the past year, has a market value of $9.5 billion